Indication: Myotonic dystrophy type 1 (DM1)

Source: J Neurol 2002 Dec;249(12):1717-22.

Research: The safety and efficacy of creatine monohydrate (Cr) was assessed in myotonic dystrophy (DM1) in a double-blind, cross-over trial. Thirty-four patients with defined DM1 were randomized to receive Cr and placebo for eight weeks (10.6 g day 1-10, 5.3 g day 11-56) in one of two treatment sequences.

Results: There was no significant im­provement using manual and quantitative muscle strength, daily life activities and patients’ own global assessment comparing verum with placebo administration. Cr supplementation was well tolerated without clinically relevant side effects, but did not result in significant improvement of muscle strength or daily-life activities.